Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.
[feedzy-rss feeds="https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=10-k&dateb=&owner=include&count=20" feed_title="no" title="160" meta="no" summary="no" thumb="no" ]
Cash Balance. Trading Below Cash? Institutional Holding. Insider Ownership.
Market Cap. Current Price. 52-week low. Difference from Low in Percentage. Average Volume. Current Volume.
Short Volume. Short Ratio. Short Outstanding. Short Squeeze?
PDUFA Date. Trial Results Date. AdComm Date. Earnings Date. Other Catalysts.
Fetch from opinions we will provide. Do the code, we will add opinions in database as we go on.
Our articles feed
Web articles feed
Press releases feed